Freek Verheugt Shamir Mehta of McMaster University told Audio Medica in Stockholm about the OASIS-5/MICHELANGELO results comparing the new anti-thrombotic therapy, fondaparinux, with enoxaparin among
Freek Verheugt
Shamir Mehtaof McMaster University told Audio Medica in Stockholm about the OASIS-5/MICHELANGELO results comparing the new anti-thrombotic therapy, fondaparinux, with enoxaparin among patients with acute coronary syndromes. For a comment on Shamir Mehta’s presentation at the ESC meeting, Audio Medica questionedFreek Verheugtof Nijmegen.
Shamir Mehta:
Freek Verheugt:
Related Episodes
Routine Angioplasty Recommended After Thrombolysis
Warren Cantor Tony Gershlick REFERENCE: Abstract 2404-3 SCAI-ACCi2 Late-Breaking Clinical Trials II: Acute Myocardial Infarction Warren Cantor, University of Toronto COMMENT: Tony Gershlick, Leicester
Debate: Adjuvant Chemotherapy Should Be Standard in Stage I Non-Small Cell Lung Cancer
Giorgio Scagliotti Robert Pirker GIORGIO SCAGLIOTTI, University of Turin ROBERT PIRKER, Medical University of Vienna A heated debate took place at the European Congress on Lung Cancer in Turin between
Front Line Therapy in Non-Small Cell Lung Cancer
Nick Thatcher NICK THATCHER, Christie Hospital, Manchester There is a proven benefit in survival if you give your patients cis-platinum based chemotherapy after resection for non-small cell lung cance